Cytolytic cells induce HMGB1 release from melanoma cell lines - PubMed (original) (raw)
doi: 10.1189/jlb.0306169. Epub 2006 Sep 12.
Affiliations
- PMID: 16968820
- DOI: 10.1189/jlb.0306169
Cytolytic cells induce HMGB1 release from melanoma cell lines
Norimasa Ito et al. J Leukoc Biol. 2007 Jan.
Abstract
High mobility group box 1 (HMGB1) is one of the recently defined damage-associated molecular pattern molecules, passively released from necrotic cells and secreted by activated macrophage/monocytes. Whether cytolytic cells induce HMGB1 release from tumor cells is not known. We developed a highly sensitive method for detecting intracellular HMGB1 in tumor cells, allowing analysis of the type of cell death and in particular, necrosis. We induced melanoma cell death with cytolytic lymphokine-activated killing (LAK) cells, tumor-specific cytolytic T lymphocytes, TRAIL, or granzyme B delivery and assessed intracellular HMGB1 retention or release to investigate the mechanism of HMGB1 release by cytolytic cells. HMGB1 release from melanoma cells (451Lu, WM9) was detected within 4 h and 24 h following incubation with IL-2-activated PBMC (LAK activity). HLA-A2 and MART1 or gp100-specific cytolytic T lymphocytes induced HMGB1 release from HLA-A2-positive and MART1-positive melanoma cells (FEM X) or T2 cell-loaded, gp100-specific peptides. TRAIL treatment, however, induced HMGB1 release, and it is interesting that this extrinsic pathway-mediated cell death was blocked with the pancaspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. Conversely, granzyme B delivery did not induce HMGB1 release. HMGB1, along with other intracellular factors released from tumor cells induced by cytolysis, may be important components of the disordered tumor microenvironment. This has important implications for the immunotherapy of patients with cancer. Specifically, HMGB1 may promote healing or immune reactivity, depending on the nature of the local inflammatory response and the presence (or absence) of immune effectors.
Similar articles
- High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. Dong Xda E, et al. J Immunother. 2007 Sep;30(6):596-606. doi: 10.1097/CJI.0b013e31804efc76. J Immunother. 2007. PMID: 17667523 - Bacille-Calmette Guèrin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1.
See WA, Zhang G, Chen F, Cao Y, Langenstroer P, Sandlow J. See WA, et al. BJU Int. 2009 Jun;103(12):1714-20. doi: 10.1111/j.1464-410X.2008.08274.x. Epub 2008 Dec 22. BJU Int. 2009. PMID: 19154459 - C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells.
Kawahara K, Biswas KK, Unoshima M, Ito T, Kikuchi K, Morimoto Y, Iwata M, Tancharoen S, Oyama Y, Takenouchi K, Nawa Y, Arimura N, Jie MX, Shrestha B, Miura N, Shimizu T, Mera K, Arimura S, Taniguchi N, Iwasaka H, Takao S, Hashiguchi T, Maruyama I. Kawahara K, et al. Cardiovasc Pathol. 2008 May-Jun;17(3):129-38. doi: 10.1016/j.carpath.2007.08.006. Epub 2007 Oct 24. Cardiovasc Pathol. 2008. PMID: 18402807 - The mechanism of organophosphorus pesticide-induced inhibition of cytolytic activity of killer cells.
Li Q, Kawada T. Li Q, et al. Cell Mol Immunol. 2006 Jun;3(3):171-8. Cell Mol Immunol. 2006. PMID: 16893497 Review. - Masquerader: high mobility group box-1 and cancer.
Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Ellerman JE, et al. Clin Cancer Res. 2007 May 15;13(10):2836-48. doi: 10.1158/1078-0432.CCR-06-1953. Clin Cancer Res. 2007. PMID: 17504981 Review.
Cited by
- Gastric alarmin release: A warning signal in the development of gastric mucosal diseases.
Wu E, Zhu J, Ma Z, Tuo B, Terai S, Mizuno K, Li T, Liu X. Wu E, et al. Front Immunol. 2022 Oct 6;13:1008047. doi: 10.3389/fimmu.2022.1008047. eCollection 2022. Front Immunol. 2022. PMID: 36275647 Free PMC article. Review. - The mechanism of HMGB1 secretion and release.
Chen R, Kang R, Tang D. Chen R, et al. Exp Mol Med. 2022 Feb;54(2):91-102. doi: 10.1038/s12276-022-00736-w. Epub 2022 Feb 25. Exp Mol Med. 2022. PMID: 35217834 Free PMC article. Review. - Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances.
Kwan A, Winder N, Muthana M. Kwan A, et al. Viruses. 2021 Jun 11;13(6):1128. doi: 10.3390/v13061128. Viruses. 2021. PMID: 34208264 Free PMC article. Review. - Eotaxins and Their Receptor as Biomarkers of Colorectal Cancer.
Zajkowska M, Kulczyńska-Przybik A, Dulewicz M, Safiejko K, Juchimiuk M, Konopko M, Kozłowski L, Mroczko B. Zajkowska M, et al. J Clin Med. 2021 Jun 17;10(12):2675. doi: 10.3390/jcm10122675. J Clin Med. 2021. PMID: 34204490 Free PMC article. - From Allergy to Cancer-Clinical Usefulness of Eotaxins.
Zajkowska M, Mroczko B. Zajkowska M, et al. Cancers (Basel). 2021 Jan 3;13(1):128. doi: 10.3390/cancers13010128. Cancers (Basel). 2021. PMID: 33401527 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous